ArticleCommunications biology2025
Monoclonal antibody generation by controlled immunoglobulin gene rearrangements.
Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Current GMP standards for the large-scale production of monoclonal antibodies.Bioengineering & translational medicine · 2026Review
- Identification of a novel N-terminal linear B-cell epitope on the FIPV nucleocapsid protein by a monoclonal antibody.BMC veterinary research · 2026Article
- Unique chicken B cell development: species-specific mechanisms and contradictory requirements of B cell receptor for post-hatched B cell development.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Monoclonal antibodies (mAbs) are essential for various applications including experimental reagents, diagnostics, and therapeutics. Thus, the platform technologies that stably generate antigen-specific mAbs are increasingly crucial. We previously developed a method to generate mAbs, termed the "ADLib system", utilizing the avian-derived B cell line DT40. Avian immunoglobulin (Ig) genes diversify principally through gene conversion-a kind of homologous recombination. The ADLib system isolates antigen-specific clones from libraries constructed using DT40 cells treated with Trichostatin A (TSA), a histone deacetylase inhibitor that enhances gene conversion frequencies. The obtained antigen-specific clones are cultured without TSA to minimize further diversification. However, low-frequency spontaneous gene conversion still occurs, potentially leading to gradual changes in the specificity of the clones. To address this, we engineered conditional mutants of activation-induced deaminase (AID), the initiator of gene conversion, using auxin-inducible degron system which enables targeted protein degradation via the auxin-dependent ubiquitin-proteasome pathway. The addition of the phytohormone auxin led to the degradation of degron-tagged AID proteins, effectively halting gene conversion. Subsequently, we carried out the ADLib system using these clones and successfully isolated antigen-specific mAbs. These suggest that our AID conditional mutants provide a powerful tool for generating and stabilizing antigen-specific clones isolated by the ADLib system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.